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In several murine tumor models the adoptive transfer of sensitized lymphoid 
cells is capable of mediating the regression of established tumor (1-3).  Identifi- 
cation  of the  most  appropriate  cells  for  use  in  adoptive  transfer  is  a  major 
problem.  While cells specifically sensitized in vivo or in  vitro to unique cancer 
antigens can be highly effective, it is often difficult to obtain these cells because 
of the poor immunogenicity of many murine tumors. This problem is especially 
cogent in considering human  tumors in which poor immunogenicity and prob- 
lems with availability of suitable preparations of human  tumor cells for in vitro 
sensitization also exist. 
In both  mice and  humans  we have extensively studied,  in vitro,  the activity 
and specificity of activated killer cells. These cells can be generated in vitro by 
exposure of normal lymphocytes to interleukin  2 (IL-2)  1 (4, 5), lectins (6, 7), or 
pooled alloantigens (8). These activated cells recognize and lyse fresh autologous 
(in the human)  or syngeneic (in  the mouse) natural  killer (NK)-resistant cancer 
cells, but do not lyse normal cells. The serologic phenotype of the precursor and 
effector cells of these activated killer cells has been extensively studied in mouse 
and man (4, 7, 8). The biologic role of activated killer cells is unknown, though 
it is known they can lyse tumor cells in Winn assays (9-1 1). However, because of 
the  ease  of generation  of these  cells  and  their  potential  applicability  to  the 
treatment  of human  tumors  we have explored  the  possible use of these  cells, 
adoptively  transferred,  in  the  treatment  of a  highly  metastatic  and  virulent 
murine tumor. This report is the first demonstration that lymphokine-activated 
killer  cells (LAK  cells),  activated  in  vitro  by IL-2,  can  inhibit  the  growth  of 
established melanoma pulmonary metastases. The kinetics of this phenomenon, 
the  nature  of the  cells involved, and  the  in  vitro activation  stimulus  required 
have been studied. 
* Reprint requests should be addressed to Dr. S. A. Rosenberg,  Chief  of Surgery, National Cancer 
Institute, Bethesda, MD 20205. 
i Abbreviations used in this paper: C', complement; CM, complete medium; E, erythrocyte; HBSS, 
Hanks' Balanced Salt Solution; IL-2, interleukin 2; LAK, lymphokine-activated killer cells; NK, 
natural killer cells; PMA, phorbol 12-myristate-13-acetate; SDS-PAGE, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis. 
J. EXp. MED. © The Rockefeller University Press  • 0022-1007]84]02]0495]  13 $1.00  4 95 
Volume 159  February  1984  495-507 496  IN  VIVO  EFFECTS OF  INTERLEUKIN 2-ACTIVATED LYMPHOCYTES 
Materials and  Methods 
Animals.  C57BL/6  mice were obtained from The Jackson Laboratory (Bar Harbor, 
ME) and the animal production facilities of the National Institutes of Health and used in 
experiments when 12 wk or older. 
Splenoc~,tes.  Spleens were removed aseptically and crushed with the hub of a syringe in 
complete medium (CM),  which consisted of RPMI  1640 (Biofluids, Rockville, MD) with 
0.1  mM nonessential amino acids and 1 ~m sodium pyruvate (Microbiological Associates, 
Walkersville, MD),  5  ×  10-SM  2-mercaptoethanol,  100  #g/ml streptomycin,  100  U/ml 
penicillin 0.03% glutamine (NIH Media Unit), and 10% heat-inactivated fetal calf serum 
(Gibco Laboratories, Grand Island, NY). The cell suspension and spleen fragments were 
passed through  a  single  layer of  10-gauge  nylon  mesh and  the  erythrocytes (E)  lysed 
osmotically with buffered ammonium chloride solution at room temperature for 2 min. 
The cells were then centrifuged and washed two times with Hanks' Balanced Salt Solution 
(HBSS, Gibco). Fresh splenocytes prepared in this way were used for LAK cell production 
or as control effector cells. In the experiments with spleens from tumor-bearing mice (see 
Fig. 4), splenocytes harvested from mice injected with 105 B 16 cells 2 wk previously were 
used for LAK cell production. 
IL-2 Preparations.  IL-2 production by concanavalin A pulsing (Con A pulse IL-2) of 
murine splenocytes has been previously described (12). Briefly, BALB/c splenocytes were 
incubated for 2 h with  10 #g/ml Con A (Miles Laboratories, Elkhart, IN), then washed 
three times in HBSS and resuspended in CM for 24 h.  Supernatants were collected by 
centrifugation,  passed  through  0.45-tsm  filters  (Millipore  Corp.,  Bedford,  MA),  and 
refrigerated until use. 
EL-4 I L-2 was produced as described previously (13). An EL-4 thymoma line (gift of  J. 
Farrar,  NIH)  was  maintained  in  RPMI  1640  with  3%  fetal  calf serum  and  0.03% 
glutamine. Cells were washed twice in HBSS and placed at  106 cells/ml in  RPMI  1640 
with  0.03%  glutamine,  50  ttg/ml  gentamicin,  and  10  ng/ml  phorbol  12-myristate-13- 
acetate (PMA) without serum for 48 h at 37°C. Collected supernatants were concentrated 
100-fold  using  a  Pellicon  Mi]]ipore concentrator  with  a  10,000-dalton  exclusion  limit 
(Millipore),  filtered  (0.45  #m  filter,  Nalgene  Labware,  Rochester,  NY),  precipitated 
between 50% and 75% ammonium sulfate, and dialyzed as described previously (14). 
Pure human IL-2 from Jurkat cells was kindly supplied by Dr. Richard Robb (Dupont 
Co.) and was prepared as reported elsewhere (15).  Purity of the IL-2 was assessed by both 
two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and sequencing the NHs-terminal peptide. Jurkat IL-2 was diluted in CM before use. The 
dilutions used for LAK generation of Con A pulse IL-2, EL-4 IL-2, and Jurkat IL-2 were 
1:2,  1:20, and 1:5,000, respectively. 
Lymphokine Activation.  Fresh C57BL/6 splenocytes were placed into 175 cm  s (750 ml) 
flasks (Falcon Labware, Oxnard, CA) laid supine, in 175 ml of CM containing the optimal 
dilution of the particular IL-2 used, at a cell concentration of 2.5 x  106/ml. No IL-2 was 
added to control flasks.  The flasks were incubated at 37°C,  5% COs for 72-96 h. The 
cells were then harvested into sterile 250-ml centrifuge tubes (Falcon), washed three times 
with  HBSS,  and  finally  resuspended  in  HBSS  for  intravenous  injection.  Before each 
injection aliquots of the LAK or control cells were taken and tested for cytotoxicity in 
vitro. 
In  Vitro  Q~totoxicit~, Assay.  18-h 5~Cr release assays were used as described previously 
(16).  Briefly, tumor target cells were labeled with 400 ~Ci of Na 51Cr assay (Amersham/ 
Searle, Arlington Heights,  IL) for  120  min in 0.5  ml of CM.  They were then washed 
three times with CM and added at 5 ×  103 cells/well to various numbers of the effector 
cells in round-bottomed microtiter plates (Linbro Scientific Co., Hamden, CT). The plates 
were incubated for 18 h at 37°C in 5% COs and the culture supernatants then harvested 
with the Skatron  Titertek System (Skatron A.  S.  Lierbyen, Norway) and counted  in a 
gamma counter.  Maximum isotope release was measured by incubation of the targets in 
with 0.1  N  HCI. Spontaneous release was measured by incubation of the targets in CM MAZUMDER  AND  ROSENBERG  497 
alone. The percentage of iysis was calculated by: 
Experimental cpm  -  spontaneous cpm 
%  lysis =  Maximal cpm  -  spontaneous cpm  x  100%. 
All determinations were made in triplicate and data are reported as the mean _+ standard 
error of the mean at an effector to target ratio of 10:1, unless otherwise specified. 
hi Vivo Assay of Adoptive Immunotherapy.  Cryopreserved cells from the B16  melanoma 
tumor line of C57BL/6 origin (17) were thawed and placed into tissue culture in CM for 
12-18  h.  The  monolayer was  then  treated with  trypsin and  the  cells obtained washed 
once with CM and then washed twice and resuspended with HBSS. Between  1 ×  10 ~ and 
2  x  105  B16  tumor  cells were  injected into the tail veins of C57BL/6  mice that  were 
greater than  12 wk old. In preliminary experiments (data not shown), pulmonary tumor 
nodules were found to be established within 3 d after injection (visually and histologically). 
LAK or control cells (usually 1 ×  108 in  1 ml HBSS) were then infused into the tail vein 
at the times after tumor rejection mentioned in the experiments. On day 15 after tumor 
induction,  the  animals  were  sacrificed, the  lungs  harvested,  and  metastatic pulmonary 
nodules counted in a  blinded fashion without knowledge of the treatment of that mouse. 
The complete enumeration of the metastases is possible because they formed black nodules 
on the surface of the lungs, as confirmed by histology. 
In the spontaneous metastasis model shown in Fig. 1,  106 B 16 tumor cells were injected 
into  the  right  hind  footpad  and  allowed  to  metastasize  spontaneously  to  the  lungs. 
Numerous pulmonary nodules were established by the time the primary tumors were ~1 
cm in diameter. The right hind limb containing the primary tumor was then amputated 
and LAK cells were administered intravenously 3 d  later.  15 d  after the amputation, the 
FIGURE  1.  Representative lungs of a mouse from the group given no treatment (left) or LAK 
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lungs were harvested and the metastases counted as above. 
When mentioned, 50 mg/kg or 150 mg/kg of cyclophosphamide (cytoxan) was infused 
intravenously 5-6 h before the transfer of the LAK or control cells. 
For the survival studies shown in Fig. 3,  l  X  108 LAK cells or fresh splenocytes were 
administered on days 3, 5, and 7 after tumor induction and the mice followed daily for 
survival. 
p values were obtained by analysis using standard t-test statistics. 
Cell Surface  Phenotype Determination.  All depletion  experiments  were  performed  in 
cytotoxicity medium composed of RPMI  1640,  0.3%  bovine serum albumin (Pathocyte 
5;  Miles  Laboratories,  Elkhart,  IN),  and  25  mM  Hepes  buffer.  Thy-l.2  +  cells  were 
removed  by  treatment  with  newborn  rabbit  complement  (C')  plus  an  anti-Thy-l.2 
monoclonal antibody (New England Nuclear, Boston, MA). Lymphocyte suspensions were 
adjusted to a concentration of 107 celis/ml in cytotoxicity medium containing the optimal 
concentration of antibody (1:200), and incubated in the cytotoxicity medium for 30 min 
at 37°C with intermittent agitation. The cells were then centrifuged and resuspended in 
one-half the original volume with a  1:5 dilution of low toxicity complement (Cedar Lane, 
Bethesda, MD). Incubation was continued for an additional 60 rain at 37°C and the cells 
were then washed three times in HBSS and resuspended in CM for further study. LAK 
cells treated with C' alone or with neither C'  nor antibody were included as controls. 
Treatments with antibody plus complement were done either before or after lymphokine 
activation. In vitro cytotoxicity was assayed before adoptive transfer. 
Results 
LAK  Cells Exert Antitumor  Effects  In  Vivo.  C57BL/6  mice,  injected intrave- 
nously with  B16  tumor cells,  were given  LAK cells,  fresh splenocytes, or  no 
treatment on day 3 of tumor growth and the effects on metastasis development 
assayed on day 15. The cytotoxicity of the LAK cells infused was 72 -4-_ 3%, while 
that of the fresh splenocytes was 5 _+ 4%. Table I shows the number of metastases 
counted  in  each  group,  in  a  blinded  fashion.  The  group  given  LAK  cells 
intravenously had fewer lung metastases (mean of 14) than the control groups 
(means of 83  and  87  for the mice given no treatment and fresh splenocytes, 
respectively; p  value <  0.01)  (Fig.  1).  Fresh splenocytes had no antimetastatic 
effect compared with the group given no therapy (p value >  0.5).  Thus,  the 
TABLE  I 
In Vivo Antitumor Effect of LAK Cells 
Cell trans-  None  Fresh splenocytes  LAK cells  ferred* 
Mean 
No. of metastases* 
142  121  15 
101  108  12 
81  161  12 
64  34  3 
101  51  18 
45  73  22 
49  5__._99  -- 
83  87  14 
* 3 d after tumor induction by systemic administration of 2 ×  105 BI6 
cells, C57BL/6  mice were given no therapy or infused intravenously 
with 1 ×  108 syngeneic fresh splenocytes or LAK cells. 
~: 15 d after tumor induction, the lungs were harvested and the metastases 
counted blindly, as described in the text. MAZUMDER  AND  ROSENBERG  499 
adoptive transfer of LAK cells can significantly decrease pulmonary B 16 mela- 
noma metastases. 
Treatment of Spontaneous Metastases by Transfer of LAK  Cells.  The  effect  of 
intravenous administration  of LAK cells on B16 tumor nodules in the lung that 
had spontaneously metastasized from a  large primary in the right hind footpad 
was  investigated.  Fig.  2  illustrates  that  the  infusion  of LAK  cells  3  d  after 
amputation of the right hind limb caused a significant decrease (p <  0.01) in the 
number of spontaneous lung metastases counted on day 15 compared with mice 
given no treatment (4 +  2 vs. 22 _+ 3 nodules). The LAK cells were cytotoxic in 
vitro (72 _+ 4% lysis).  Thus,  the adoptive transfer of LAK cells can also cause a 
significant decrease in spontaneous B16 melanoma lung metastases. 
Transfer of LAK Cells Can  Increase Survival  Time.  We  wished  to  determine 
whether the marked decrease in number of metastases caused by the intravenous 
administration  of LAK cells led to an improvement in survival.  Because of the 
reported requirement for immunosuppression in other mouse models of adoptive 
immunotherapy we performed this experiment in mice pretreated with 500 rads 
whole body irradiation  (18). The infusion of LAK cells on days 3, 5, and 7 after 
tumor  induction  into  C57BL/6  mice  bearing  B16  melanoma  lung  metastases 
significantly lengthened survival time (52 _+ 1 d) compared with irradiated  mice 
given no therapy (21  4"  1 d; p  <  0.01) (see Fig.  3).  Fresh splenocytes given on 
the same days had no effect on the survival time (27 +  1 d, p >  0.5). The in vitro 
cytotoxicity of the LAK cells was 48 _  4%, while that of the fresh cells was 5 +-. 
1%.  Thus,  the  adoptive  transfer  of LAK  cells  leads  to  a  significant  survival 
advantage. 
Optimization of Treatment with LAK Cells.  In order to optimize treatment with 
LAK cells, we investigated the effects of LAK cell administration at various times 
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FIGURE 2.  Decrease in spontaneously generated B16 pulmonary metastases caused by the 
intravenous adoptive  transfer of LAK  cells.  B16  melanoma,  injected  into  the  right  hind 
footpad,  spontaneously metastasized to the lungs.  1  x  10  s syngeneic LAK cells (generated 
using Con A  pulse II-2) were transferred intravenously 3 d  after amputation of the involved 
limb and the number of lung nodules counted blindly  12 d  later, as described in the text. 
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FIGURE 3.  The adoptive transfer of LAK cells leads to a significant increase in survival time. 
C57BL/6 mice were irradiated with 500 rads and then induced intravenously with 1 x  l0  s 
B16 cells. On days 3, 5, and 7 of tumor growth, 1 x  108 LAK cells or fresh splenocytes were 
infused into two groups with another group receiving no therapy. The mice were then followed 
for length of survival. 
after tumor induction with or without prior chemotherapy with cytoxan. It can 
be seen from Fig. 4 that LAK cells infused 7 or 11 d after tumor induction could 
exert significant antitumor  effects (p  <  0.05),  although  administration  at  3  d 
after induction,  was better (p <  0.01).  It was also found that  cytoxan infused 
alone or 5 to 6 h before the LAK cell infusions on day 3 had no effect on the in 
vivo efficacy of LAK cells (groups  5,  6,  7  vs.  8,  9,  10,  respectively; p  >  0.5). 
Again here, fresh splenocytes (group 3) had no in vivo antitumor effects. 
We also wished to determine whether incubation with IL-2-containing super- 
natants was required for the generation of the in vivo effector cell, i.e., whether 
incubation  in  CM  containing  xenogeneic serum  was  sufficient.  Fig.  4  demon- 
strates that splenocytes incubated in CM (group 4) alone had no antimetastatic 
effect in vivo or may have led to a  slight increase in the number of metastases. 
The  in  vitro cytotoxicity of the  LAK  cells,  fresh  splenocytes, and  splenocytes 
incubated in CM alone were 64 +  4%, 3 _+ 4%, and 7 -+  1%, respectively. 
LAK Cells from  Tumor-bearer  Spleens Are Also Effective  in  Therapy.  In order to 
investigate whether splenocytes from tumor-bearing animals could generate LAK 
cells capable of exerting antitumor effects in vivo, we incubated splenocytes from 
normal C57BL/6 mice or mice bearing 2-wk old B16 pulmonary tumors in Con 
A  pulse  IL-2 and  administered  those  LAK cells  to  mice  with  B16  pulmonary 
metastases.  We found that LAK cells from tumor-bearing animals were equiva- 
lent to those from normal animals (14  +  2  and  15  +  3  metastases, p  >  0.5), in 
their ability to significantly decrease the number of lung metastases compared to 
control animals (52 -+ 3; p <  0.01) (Fig. 5). The in vitro cytotoxicities of the LAK 
cells from normal and tumor-bearing mice were also equivalent (51  _+ 4% and 
48 +  3%, respectively). 
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FIGURE 4.  Kinetics and chemotherapy studies; C57BL/6  mice, induced with 2  x  l0  B BI6 
melanoma cells intravenously, were split into ! 0 groups as shown. Each mouse was individually 
weighed and  150  mg/kg cytoxan was infused intravenously alone or 6 h before the adoptive 
transfer, on day 3 after tumor induction, of 1 x  10 s fresh splenocytes or 1 x  10  s splenocytes 
incubated in CM alone or on days 3, 7, or 11  of 1 X 108 LAK cells generated by Con A pulse 
IL-2. Five mice received 1 X 10"LAK cells on days 3, 7, or 11 after tumor induction without 
prior cytoxan. On day 15 after tumor induction, the lungs were harvested and the metastases 
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8  FIGURE 5.  1 ×  10  LAK cells, generated by incubation in Con A pulse IL-2, from spleens of 
5  normal mice or mice given 1 ×  10  BI6 cells intravenously 2 wk previously, were infused into 
syngeneic C57BL/6  mice bearing B16 pulmonary metastases induced intravenously. Lungs 
were harvested 15 d after tumor induction and the metastases counted blindly. Control animals 
received no treatment. 502  IN  VIVO  EFFECTS  OF  INTERLEUKIN  2-ACTIVATED  LYMPHOCYTES 
surface phenotypes of the precursor and effector cells of the LAK cell mediating 
these in vivo effects were determined  by depletion of Thy-l.2 + cells before or 
after LAK cell generation.  Fig. 6 demonstrates that treatment with complement 
(C')  plus anti-Thy-l.2  (0)  antibody  before or  after  incubation  in  lymphokine 
abolished the generation of the cells responsible for the antimetastatic effects in 
vivo (p <  0.05). Transfer of LAK cells treated with C' alone led to an equivalent 
decrease in metastases as transfer of LAK cells treated with neither antibody nor 
C'. Here again, the mice treated with cytoxan alone or cytoxan and either fresh 
(normal) splenocytes or splenocytes incubated in CM alone had the same number 
of metastases as the control  group of mice without treatment  (Fig.  6).  The  in 
vitro  tumor  lysis  induced  by  lymphokine  incubation  was  also  abolished  by 
treatment  with anti-Thy-l.2  antibody plus C'  before or after incubation  (3  __. 
4% or 5 +_  1% vs.  72 +  7% for the untreated  LAK cells and 68 _+ 4% or 75 _ 
6%  for  the  LAK cells treated  with  C'  alone  before or after  incubation).  The 
fresh splenocytes and  splenocytes in  CM alone also had  no significant  in  vitro 
cytotoxicity for tumor (7 +  4% and 9 +  5%, respectively). Thus, T  cells are the 
effector and precursor cells for the in vivo antimetastatic and in vitro cytotoxic 
LAK cells. 
LAK Activation  in  Various Growth Factors.  The lymphokine required for gen- 
eration  of  the  cell  effective  in  vivo  was  investigated  using  IL-2-containing 








-~"  .-8.-  -¢.- 
|  o 
I  I  I  I  I  I  1  I  I 
50 mg/~ dVrOXAN  + 
i 
FIGURE 6.  Phenotype of the precursors and effectors of the cells active in vivo. C57BL/6 
mice were induced with 1 x  10"BI6 cells intravenously. On day 3, they were infused with 50 
mg/kg cytoxan and 6 h later, received either no treatment, 5 x  107 fresh (normal) splenocytes, 
5 x  107 splenocytes incubated in CM alone, 5  x  10  ~ untreated LAK cells (generated in Con 
A pulse II-2),  or 5 x  l0  T LAK cells treated with complement (C') alone or with C' plus anti- 
Thy-1.2 (0) antibody either before or after lymphokine activation. The lungs were then assayed 
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FIGURE 7.  Activation in various IL-2-containing media• C57BL/6 mice, induced with 1 x 
105  B16  cells intravenously, were infused on day  3  with  5  X  l0  T splenocytes activated in 
partially purified EL-4 or Con A pulse IL-2 or pure human Jurkat IL-2 with control animals 
receiving no treatment. Metastases were counted on day 15 as described in the texts. 
human Jurkat IL-2 (purified to molecular homogeneity) led to equivalent gen- 
eration of cells active in vivo as did the partially purified Con A pulse or EL-4 
IL-2, all of which activated cells capable of significantly decreasing the number 
of B16 metastases (p <  0.01).  Furthermore, incubation in all of the various IL- 
2  preparations  led to  the induction of equivalent levels of in  vitro antitumor 
cytotoxicity (48 +  4% for the Con A pulse IL-2, 54 +  7% for the EL-4 IL-2, and 
41  +  6%  for the pure Jurkat IL-2). Thus, the lymphokine responsible for the 
generation of the cells effective in vivo is probably IL-2. 
Discussion 
Numerous reports have suggested that lymphocytes specifically sensitized in 
vitro to primary or metastatic tumor cells are capable of antitumor effects in 
vivo (1-3,  19). However, such highly purified and immunogenic tumor cells are 
frequently unavailable in  the human.  Furthermore, several investigators have 
demonstrated antigenic heterogeneity between primary and metastatic tumors, 
with subsequent resistance to lysis by sensitized syngeneic lymphocytes (20, 21). 
Such problems led us to seek alternative methods of generating lytic cells with 
antitumor reactivity, e.g. incubation in lymphokines (4, 5), lectins (6, 7), or mixed 
lymphocyte cultures (8).  We  have now developed an  in  vivo tumor model in 
order to test whether this approach of activating cells in vitro without requiring 
tumor in the culture was capable of generating cells active in vivo. This paper 
represents  the  first  report  of the  therapeutic efficacy in  vivo  of systemically 
administered LAK cells against established metastatic tumor. 
The intravenous adoptive transfer of LAK cells, generated within 3 to 4 d  in 
vitro by incubating splenocytes in IL-2, can lead to a significant decrease in the 
number of established B 16 melanoma pulmonary metastases. This was found to 
be true whether the metastases were generated by intravenous injection of the 
B 16 tumor cells or spontaneously from a primary tumor that was removed before 
LAK cell transfer. The latter model is of particular clinical relevance, since the 504  IN  VIVO  EFFECTS  OF  INTERLEUKIN  2-ACTIVATED  LYMPHOCYTES 
observation  of puhnonary  metastases  after amputation  of a  primary  tumor  is 
often  made.  Important  to the  therapeutic  relevance  of these  LAK cells is  the 
finding  that  they were equally active  in  vivo even  when  they were generated 
from spleens of animals bearing large tumors. This equivalence of tumor-bearer 
and  normal  splenocytes  through  this  activation  is  encouraging  in  the  face of 
numerous  reports  suggesting  the  presence  of suppressor  cells  in  hosts  with 
neoplasia, especially in its late stages (22-24). 
The antitumor effects seen in vivo after administration  of LAK cells leads to 
a significant increase in the survival time.  Radiation of the mice was performed 
before tumor injection in the experiments determining survival advantage in an 
attempt  to diminish  any  in  vivo suppressor activity (18).  In  this regard  it is of 
interest that the administration  of cytoxan in vivo before LAK infusion did not 
increase the antitumor effects in spite of the large number of reports demonstrat- 
ing the presence of cytoxan-sensitive cells that  can enhance tumor growth and 
suppress in  vitro or in vivo cell-mediated responses (25,  26).  It appears that  in 
this model, the cytoxan-sensitive suppressor cells do not play a major role. 
It appears that  NK cells do not play a  major role in this  therapeutic  model. 
This  is  evidenced  by  the  inability  of the  large  number  of fresh  splenocytes 
transferred as controls to mediate any antitumor effects in vivo, unlike the data 
in some other tumor models (27, 28). Also, the phenotype of the precursor and 
effector cell active in vivo appears to be that of a T  cell, and, in fact, the in vitro 
tumor  lysis  is  also  mediated  by cells  bearing  the  T  cell  phenotype  (29,  30). 
Though  we have determined that the cell mediating in vitro tumor lysis is Lyt- 
2 +, we have not determined the Lyt phenotype of the cells active in vivo. 
In order to determine the mechanism of in vitro generation of active cells, we 
have demonstrated  that the generation  of the cells active in vivo is not due to 
any xenogeneic serum components or other tissue culture artifacts of the medium 
of incubation, a possibility that concerned us due to the reports of activation of 
immune cells by fetal calf serum or 2-mercaptoethanol alone (31, 32). In fact, it 
appears that some IL-2-containing medium is required for the generation of the 
therapeutic cells, and the efficacy in vivo of the splenocytes activated by the pure 
Jurkat IL-2 suggests that it is the IL-2 molecule itself that is responsible for this 
generation. 
The mechanism of the antitumor effects in vivo of the LAK cells is unknown 
at present.  It is possible that it is due to direct antitumor  cytotoxicity, since the 
cytotoxic LAK cells are active in vivo, while the noncytotoxic fresh splenocytes 
or splenocytes incubated in CM are not. In most models of antitumor immtlnity 
using specifically sensitized splenocytes, the Ly-1 ÷ or helper class of lymphocytes 
appears to be instrumental  (2), possibly by the recruitment of host effector cells 
through  local production  of lymphokines (33).  It is possible that  the activated 
LAK cells and not the control cells (fresh splenocytes or splenocytes incubated 
in CM alone) express such lymphokines in vivo. 
Finally,  the  reason  for our inability  thus far  to completely cure mice of the 
B16 pulmonary metastases is unknown.  It is possible that the migration  of such 
activated cells is not optimal,  with little or no lymphatic recirculation  or abun- 
dance at sites of tumor as evidenced by the abnormal homing patterns of T  cell 
clones and lines (34,  35) or of IL-2-activated cells in the human  (36).  Perhaps MAZUMDER  AND  ROSENBERG  505 
methods of local delivery of such cells,  or overwhelming  their  normal  in  vivo 
clearance mechanisms may be clinically advantageous (37).  It should be empha- 
sized that we have only studied the ability of LAK cells to diminish lung metastases 
and  cannot  comment on the ability of these cells to affect metastases at other 
sites. 
The presence of suppressor cells within the infused LAK population is another 
possible problem and may be overcome by the removal of tumor-enhancing cells 
(38). It is also likely that the activity of the LAK cells in vivo is short lived, similar 
to their  rapidly  vanishing  cytotoxic activity in  vitro when  removed from  IL-2 
(data not shown). This would then necessitate the concomitant in vivo adminis- 
tration of IL-2, as shown in some other systems (39). Studies investigating these 
therapeutic protocols are in progress. 
Summary 
In previous in vitro studies, we have shown that murine splenocytes or cancer 
patient  lymphocytes  incubated  in  IL-2  become  lytic  for  fresh  syngeneic  or 
autologous  tumors.  We  have  now  performed  the  adoptive  transfer  of such 
lymphokine-activated killer (LAK) cells in a murine B 16 metastasis model to test 
their  in  vivo efficacy.  1 x  108 LAK cells, infused intravenously into C57BL/6 
mice with  established  B16 pulmonary  metastases,  led to a  marked decrease in 
the number of lung nodules and improved survival. LAK cells administered  3 d 
after amputation  of a tumor-bearing limb also decreased the incidence of spon- 
taneous pulmonary metastases.  LAK cells generated from tumor-bearer spleno- 
cytes had effects equivalent to those from normal animals, and this antimetastatic 
effect of the LAK cells did not require the prior administration of cyclophospha- 
mide or other immunosuppressants.  Fresh or unstimulated  splenocytes had  no 
effect. The antitumor effectors and precursors in vivo and in vitro were Thy-1 +. 
The lymphokine required for the activation appeared to be interleukin  2 (IL-2), 
since  incubation  in  partially  purified  supernatants  from  PMA pulsed  EL-4  or 
Con A-pulsed splenocytes or purified Jurkat IL-2 led to the generation of LAK 
cells equally active in vivo. The use of IL-2-activated cells may provide a valuable 
method for the adoptive therapy of human neoplasms as well. 
Received for publication 30 August 1983 and in ret,  ised  form 17 October 1983. 
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